Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Revenue (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Revenue for 3 consecutive years, with $15.0 million as the latest value for Q1 2025.

  • On a quarterly basis, Revenue changed N/A to $15.0 million in Q1 2025 year-over-year; TTM through Sep 2025 was $15.0 million, a 683.66% increase, with the full-year FY2023 number at $6.9 million, changed N/A from a year prior.
  • Revenue was $15.0 million for Q1 2025 at Centessa Pharmaceuticals, up from -$2.6 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $15.0 million in Q1 2025 to a low of -$2.6 million in Q4 2023.
  • A 3-year average of -$242555.6 and a median of -$2.2 million in 2022 define the central range for Revenue.
  • Biggest YoY gain for Revenue was 16.71% in 2023; the steepest drop was 56.33% in 2023.
  • Centessa Pharmaceuticals' Revenue stood at -$2.2 million in 2022, then dropped by 16.71% to -$2.6 million in 2023, then surged by 683.66% to $15.0 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Revenue are $15.0 million (Q1 2025), -$2.6 million (Q4 2023), and -$2.5 million (Q3 2023).